Online citations, reference lists, and bibliographies.
← Back to Search

HER-2/neu Oncogene Protein And Prognosis In Breast Cancer.

A. K. Tandon, G. Clark, G. Chamness, A. Ullrich, W. Mcguire
Published 1989 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Amplification of the HER-2/neu oncogene was recently reported to predict poor clinical outcome in node-positive breast cancer patients. Since expression of the oncogene as its protein product might be even more closely related than gene amplification to disease progression, we have now examined levels of the HER-2/neu oncogene protein for its prognostic potential in both node-positive and node-negative breast cancer. Using Western blot analysis, levels of this protein were determined in 728 primary human breast tumor specimens. We examined relationships between this protein and other established markers of prognosis, as well as clinical outcome. In node-negative patients (n = 378), the HER-2/neu protein failed to predict disease outcome. However, in node-positive patients (n = 350), those patients with higher HER-2/neu protein had statistically shorter disease-free (P = .0014) and overall survival (P less than .0001) than patients with lower levels of the protein. Higher HER-2/neu protein was found in tumors without estrogen receptor (ER) (P = .02) or progesterone receptor (PgR) (P = .0003), and in patients with more than three positive lymph nodes (P = .04). A significant correlation between levels of the HER-2/neu gene protein and amplification of the gene itself was also found (n = 48, P less than .001). Multivariate analyses in these patients showed that the HER-2/neu protein is a significant independent predictor of both the disease-free and the overall survival in node-positive breast cancer, even when other prognostic factors are considered.
This paper references
10.1002/1097-0142(19880201)61:3<420::AID-CNCR2820610303>3.0.CO;2-0
DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens
L. Dressler (1988)
10.1016/S0140-6736(87)92736-X
OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION
DeonJ. Venter (1987)
10.1002/j.1460-2075.1985.tb04016.x
Antibodies to the autophosphorylation sites of the epidermal growth factor receptor protein‐tyrosine kinase as probes of structure and function.
W. Gullick (1985)
10.1016/0003-2697(85)90442-7
Measurement of protein using bicinchoninic acid.
P. Smith (1985)
10.1007/978-1-4612-4380-9_37
Regression Models and Life-Tables
D. Cox (1972)
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
D. Zhou (1987)
10.1056/NEJM198811103191902
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
M. J. van de Vijver (1988)
Evaluation of survival data and two new rank order statistics arising in its consideration.
N. Mantel (1966)
10.1073/PNAS.76.9.4350
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
H. Towbin (1979)
10.1016/0092-8674(83)90169-1
Transposition and amplification of oncogene-related sequences in human neuroblastomas
N. Kohl (1983)
Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.
J. Drebin (1988)
10.1016/S0140-6736(87)90593-9
EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER
J. Richard (1987)
10.2307/1402659
Analysis of Survival Data under the Proportional Hazards Model
N. Breslow (1975)
Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA.
M. J. van de Vijver (1988)
10.1126/SCIENCE.2992089
Amplification of a novel v-erbB-related gene in a human mammary carcinoma.
C. R. King (1985)
10.1038/313144A0
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
T. Libermann (1985)
10.1126/SCIENCE.6719137
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.
G. Brodeur (1984)
10.1126/SCIENCE.3012781
The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.
T. Akiyama (1986)
10.1016/0092-8674(86)90779-8
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
C. Bargmann (1986)
10.1016/0890-8508(87)90019-3
Immunohistochemical localization of c-erbB-2 in human breast carcinomas.
B. Gusterson (1987)
10.1073/PNAS.83.13.4834
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.
C. Escot (1986)
Measurement of progesterone receptor in human breast cancer biopsies.
B. Powell (1979)
10.1200/JCO.1987.5.7.999
Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease.
M. Cline (1987)
10.1073/PNAS.82.19.6497
A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.
K. Semba (1985)
10.1056/NEJM198312013092240
Progesterone receptors as a prognostic factor in stage II breast cancer.
G. Clark (1984)
Evaluation of estrogen receptor assays in human breast cancer tissue.
Mcguire Wl (1977)
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
J. Varley (1987)
10.1126/SCIENCE.2999974
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.
L. Coussens (1985)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
M. Berger (1988)
Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.
M. Tal (1988)
10.1126/SCIENCE.3289120
Amplification of c-erbB-2 and aggressive human breast tumors?
D. Slamon (1988)
10.1016/S0140-6736(86)91782-4
AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO
J. Yokota (1986)
10.1038/227680A0
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
U. Laemmli (1970)
10.1073/PNAS.84.20.7159
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
R. Hudziak (1987)
10.1126/SCIENCE.3541204
The molecular genetics of cancer.
J. Bishop (1987)
10.1146/ANNUREV.GE.18.120184.003005
The molecular genetics of cellular oncogenes.
H. Varmus (1984)
Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.
J. Yokota (1988)
10.1056/NEJM198903093201003
Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.
G. Clark (1989)
10.1200/JCO.1986.4.9.1321
Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients.
J. Lundy (1986)
10.1200/JCO.1987.5.1.55
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
G. Clark (1987)
10.1128/MCB.7.5.2019
Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.
M. van de Vijver (1987)
10.1056/NEJM198510313131802
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
R. Seeger (1985)
10.1080/00401706.1982.10487769
The Statistical Analysis of Failure Time Data
J. D. Kalbfleisch (1980)



This paper is referenced by
10.1007/s11670-011-0134-z
Breast cancer subtypes and survival in Chinese women with operable primary breast cancer
Zhao-sheng Li (2011)
10.1038/modpathol.3800411
β4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer
L. K. Diaz (2005)
10.1016/S0002-9440(10)63075-1
Tissue microarrays for rapid linking of molecular changes to clinical endpoints.
J. Torhorst (2001)
c-erbB2 expression in different histological types of invasive breast carcinoma
S. Soomro ()
10.1177/172460080301800103
Quantitative Assessment of HER-2/Neu Protein Concentration in Breast Cancer by Enzyme-Linked Immunosorbent Assay
V. Müller (2003)
10.1023/A:1005700812422
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
T. Fehm (2004)
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.
S. Oesterreich (1996)
10.1007/BF00665980
The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
N. Quénel (2004)
Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.
E. Vitetta (1994)
10.1007/s101470050003
Prognostic significance of c-erb B-2 protein status using an enzyme immunoassay in breast cancer
E. Shin (2000)
10.1016/0360-3016(92)90894-N
Therapy of small breast cancer: a prospective study on 1036 patients with special emphasis on prognostic factors.
R. Sauer (1992)
10.1093/ANNONC/5.SUPPL_4.S31
Molecular biology of breast cancer.
N. Lemoine (1994)
10.1007/BF01247465
Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy
H. Meden (2005)
10.1016/0753-3322(90)90066-I
Growth factors and oncogenes in human solid tumors: clinical aspects.
J. Bonneterre (1990)
10.1007/BF01611175
Proliferating cell nuclear antigen in breast lesions: Correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer
P. Shrestha (2005)
10.1080/07391102.2010.10507341
Structure-Based and Ligand-Based Drug Design for HER 2 Receptor
Hung-Jin Huang (2010)
10.1038/bjc.1997.284
Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma.
T. Rasmuson (1997)
10.1002/CYTO.990220404
Aneuploidy in breast cancer: a fluorescence in situ hybridization study.
S. Shackney (1995)
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
M. Press (1994)
PathVysionTM HER-2 DNA Probe Kit (LSI® HER-2/neu SpectrumOrangeTM / CEP® 17 SpectrumGreenTM)
(2001)
10.1159/000329595
Her-2/neu Overexpression Due to Polysomy 17 in Breast Cancer: Molecular Testing to Guide Therapeutic Options
R. Sahoo (2011)
Follow-up Study of HER-2 / neu Amplification in Primary Breast Cancer 1
Gary M. Clark (2006)
10.1038/bjc.1991.100
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.
W. Gullick (1991)
10.1007/s00262-006-0188-9
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine
M. Hueman (2006)
10.1093/JNCI/DJI249
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
G. Arpino (2005)
10.1016/0959-8049(93)90027-D
Quantum leaps in treatment of high-risk breast cancer? Prove it!
V. Jones (1993)
10.1007/BF00666177
The type I growth factor receptors in human breast cancer
T. Rajkumar (2004)
Identification and Role of the MTA1 Complex in Small Intestinal Carcinoids Malignancy
M. Zikusoka (2006)
10.1002/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C
Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis
P. Rosen (1995)
10.1007/978-1-4899-8050-2_11
Molecular Testing in Breast Cancer
D. Zardavas (2014)
10.1016/j.anndiagpath.2008.02.007
HER-2 status in gastrointestinal stromal tumor.
L. F. Lopes (2008)
10.1309/AJCP51HCGPOPWSCY
Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
H. Lee (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar